EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 40 / No 10 (Octobre 2024) Med Sci (Paris), 40 10 (2024) 707-710 References
Open Access
Issue
Med Sci (Paris)
Volume 40, Number 10, Octobre 2024
Page(s) 707 - 710
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2024110
Published online 25 October 2024
  1. Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol 2019 ; 39 : 277–86. [CrossRef] [PubMed] [Google Scholar]
  2. Groslambert M, Py BF. NLRP3, un inflammasome sous contrôle. Med Sci (Paris) 2018 ; 34 : 47–53. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Van Gijn ME, Ceccherini I, Shinar Y, et al. New workflow for classification of genetic variants’ pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Genet 2018 ; 55 : 530–7. [CrossRef] [PubMed] [Google Scholar]
  4. Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008 ; 29 : 803–8. [CrossRef] [PubMed] [Google Scholar]
  5. Cosson C, Riou R, Patoli D, et al. Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation. J Exp Med 2024 ; 221 : e20231200. [CrossRef] [PubMed] [Google Scholar]
  6. Fayand A, Cescato M, Le Corre L, et al. Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype. J Allergy Clin Immunol 2023 ; 152 : 1303–11.e1. [CrossRef] [PubMed] [Google Scholar]
  7. Vande Walle L, Stowe IB, Šácha P, et al. MCC950/ CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biol 2019 ; 17 : e3000354. [CrossRef] [PubMed] [Google Scholar]
  8. Weber ANR, Tapia-Abellán A, Liu X, et al. Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. Rheumatol Oxf Engl 2022 ; 61 : e299–e313. [CrossRef] [PubMed] [Google Scholar]
  9. Py BF, Kim MS, Vakifahmetoglu-Norberg H, et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013 ; 49 : 331–8. [CrossRef] [PubMed] [Google Scholar]
  10. Zhang Z, Meszaros G, He WT, et al. Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J Exp Med 2017 ; 214 : 2671–93. [CrossRef] [PubMed] [Google Scholar]
  11. Mateo-Tórtola M, Hochheiser IV, Grga J, et al. Non-decameric NLRP3 forms an MTOC-independent inflammasome. BioRxiv 2023 ; 2023.07.07.548075. [Google Scholar]
  12. Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 2018 ; 17 : 588–606. [CrossRef] [PubMed] [Google Scholar]
  13. Hochheiser IV, Pilsl M, Hagelueken G, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 2022 ; 604 : 184–9. [CrossRef] [PubMed] [Google Scholar]
  14. Jordan B. Les secrets des variants. Med Sci (Paris) 2023 ; 39 : 981–3. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.